search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Neurology India
Medknow Publications on behalf of the Neurological Society of India
ISSN: 0028-3886
EISSN: 1998-4022
Vol. 54, No. 4, 2006, pp. 354-358
Bioline Code: ni06128
Full paper language: English
Document type: Research Article
Document available free of charge

Neurology India, Vol. 54, No. 4, 2006, pp. 354-358

 en Refractory status epilepticus
Murthy JMK

Abstract

Refractory status epilepticus (RSE) is a common problem in intensive care units and emergency departments. The important risk factor predisposing patients with SE to RSE is delay in receiving treatment. Self-sustaining SE is associated with progressive, time-dependent development of pharmacoresistance. Early termination of convulsive SE by aggressive treatment is the best way to prevent RSE. RSE once develop, requires more aggressive treatment as it is associated with higher mortality and morbidity. To date, no randomized controlled trials have been done for RSE. The most experience exists with coma inducing agents like pentobarbital, midazolam and propofol. New evidence suggests for the possible role of newer AEDs.

Keywords
Anesthetic agents, burst suppression, midazolam, pentobarbital, propofol, refractory status epilepticus.

 
© Copyright 2006 Neurology India.
Alternative site location: http://www.neurologyindia.com

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 10-Sep-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil